Trial reportTrials2025
Effect of dexmedetomidine on perioperative blood glucose regulation in type 2 diabetic patients undergoing laparoscopic colorectal cancer radical resection: a randomised double-blinded controlled trial.
Trial report in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Type 2 Diabetes Mellitus in the Northern Tree Shrew (Tupaia belangeri).Journal of the American Association for Laboratory Animal Science : JAALAS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe stability of blood glucose levels in diabetic patients is more susceptible to fluctuations than in nondiabetic individuals. The effect of dexmedetomidine on glucose fluctuations in diabetic patients remains unclear. This study aimed to investigate the effect of intraoperative dexmedetomidine on glucose homeostasis in patients with type 2 diabetes undergoing laparoscopic colorectal cancer radical resection.
methods80 participants with T2DM preparing for laparoscopic colorectal cancer radical resection were randomly divided into four groups: control group (group C), dexmedetomidine 1 μg ⋅ kg
resultsCompared with the baseline levels, the levels of blood glucose from T2 to T5 in group C increased gradually but were not significantly different at each time point (p > 0.05), and there was a statistically significant rise in blood glucose in group D1 at T3, T4, and T5 and in groups D2 and D3 at T2, T3, and T4 (p < 0.05). Compared with group C, blood glucose in groups D2 and D3 was significantly higher at T3, andT4 (p < 0.05). Compared with group C, the rangeability from T1 to T3 and T1 to T4 was significantly higher in groups D2 and D3 (p < 0.05).
conclusionDexmedetomidine loading dose 1 μg/kg and a Maintenance dose 0.25 μg/kg/h can be used in type 2 diabetic patients for better glucose regulation without increasing the incidence of perioperative hyperglycemia, adverse effects, and extending extubation time.
trial registrationChiCTR2100042050. Registered on January 13, 2021, with ChiCTR. https://www.chictr.org.cn/showproj.html?proj=120133 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.